Navigation Links
CuraGen Reports Third Quarter 2008 Financial Results
Date:11/3/2008

September 30, September 30,

2008 2007 2008 2007

(unaudited) (unaudited)

Collaboration revenue $- $22 $1,174 $66

Operating expenses:

Research and development 3,453 8,074 12,459 30,480

General and administrative 1,076 2,568 4,235 9,631

Restructuring and other charges - 1,058 - 8,537

Total operating expenses 4,529 11,700 16,694 48,648

Gain on sale of intangible asset - - 36,397 -

(Loss) income from operations (4,529) (11,678) 20,877 (48,582)

Interest income 741 1,861 2,471 4,060

Interest expense (226) (1,273) (1,474) (4,172)

Gain on extinguishment of debt - 169 6,991 169

Gain on sale of long-term marketable

securities - 973 - 973

(Loss) income from continuing

operations before income taxes (4,014) (9,948) 28,865 (47,552)

Income tax benefit (provision) 32 50 (362) 160

(Loss) income from continuing

operations (3,982) (9,898) 28,503 (47,392)

Discontinued operations:

Loss from discontinued operations - - - (2,991)

Gain on sale of subsidiary - - - 78,352

Income from discontinued operations - - - 75,361

Net (loss) income ($3,982) ($9,898) $28,503 $27,969

Basic (loss) income per share from

continuing operations ($0.07) ($0.18) $0.50 ($0.85)

Basic income per share from

discontinued
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
2. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
3. CuraGen to Present at the BIO CEO & Investor Conference
4. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
5. CuraGen Corporation Receives Notification from NASDAQ
6. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
7. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
8. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
9. CuraGen Appoints Clinical Oncologist as VP of Medical Development
10. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
11. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... Dec. 19, 2014  Roche (SIX: RO, ROG; OTCQX: ... Inc. (Bina), a privately held company based in ... Bina provides a big data platform for centralized ... data. Bina,s proprietary on-market Genomic Management Solution, Bina-GMS ... to perform fast and scalable analyses to maximize ...
(Date:12/19/2014)... , Dec. 19, 2014 Research and Markets ... addition of the "Technology Innovations in Smart ... http://photos.prnewswire.com/prnh/20130307/600769 ... Smart Fabrics" offers a detailed assessment on technological ... Key Findings: 1. The Smart ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... Physical Laboratory (NPL) is working to provide more reliable measurement ... which could lead to much more accurate devices in the ... in 1986. It uses a nano-sized probe to feel the ... Braille on an extremely small scale. The technique can also ...
... SEATTLE, Oct. 20 Adaptive TCR Technologies, a ... the release of its immunoSEQ™ profiling service and ... provide researchers and clinicians the ability to profile ... level of detail that has never before been ...
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... its proprietary drug-delivery platforms to develop treatments in areas ... has submitted additional patent applications, covering its Cobalamin-mediated oral ... drugs, as a result of the growing interest surrounding ...
Cached Biology Technology:Measuring the electrical properties of nano-crystals 2Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing. 2Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing. 3Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... skin. Cancer is not a static disease but during ... defences adapting to new environmental circumstances, protecting against chemotherapy ... Until now little was known about the mechanisms ... is a particularly intriguing way in which a tumour ...
... of carbon in the world,s oceans, which cover 70 ... climate cycles, with many questions remaining unanswered. Between 200 ... "twilight zone" where insufficient sunlight penetrates for microorganisms to ... resident at these depths capture carbon dioxide that they ...
... of spring-run Chinook salmon in California by the end ... at UC Davis, the Stockholm Environment Institute and the ... for managing water resources to protect the salmon runs, ... Thompson, director of the Center for Aquatic Biology and ...
Cached Biology News:Why cancer cells change their appearance? 2Up from the depths: How bacteria capture carbon in the 'twilight zone' 2Warming streams could be the end for salmon 2
... Fixed clamp trays and universal trays ... Magnetic drive Shaking speed: ... 25 mm amplitude Clamps ... 2000 ml, including Fernbach flasks ...
... convenient, and efficient Denatured protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their Denatured condition. ... high binding capacity fo all pH values. ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Biology Products: